Abstract
Anxiety disorders are common and disabling conditions. Current drug treatment methods have limitations including resistance, delayed efficacy and side effects. The advent of sophisticated imaging techniques and the production of highly selective receptor ligands have increased our knowledge of the biological mechanisms underpinning anxiety. Our aim is to review recent discoveries in important neurological systems to provide an understanding of important current anxiolytic targets. Some of these systems, such as GABA, have been implicated in anxiety disorders for decades, but a recent greater understanding is enabling more sophisticated targeting of treatments. In other systems, including the neuropeptides, we have now developed the pharmacological tools in human subjects to begin exploring their relationship to anxiety disorders. We review GABA, serotonin, glutamate, noradrenaline, dopamine and some neuropeptides herein.
Keywords: Anxiety disorders, side effects, receptor ligands, Anxiolytic Drugs, neurological systems, neuropeptides, serotonin, glutamate, noradrenaline, dopamine
Current Pharmaceutical Design
Title: Potential Novel Anxiolytic Drugs
Volume: 14 Issue: 33
Author(s): D. Christmas, S. Hood and D. Nutt
Affiliation:
Keywords: Anxiety disorders, side effects, receptor ligands, Anxiolytic Drugs, neurological systems, neuropeptides, serotonin, glutamate, noradrenaline, dopamine
Abstract: Anxiety disorders are common and disabling conditions. Current drug treatment methods have limitations including resistance, delayed efficacy and side effects. The advent of sophisticated imaging techniques and the production of highly selective receptor ligands have increased our knowledge of the biological mechanisms underpinning anxiety. Our aim is to review recent discoveries in important neurological systems to provide an understanding of important current anxiolytic targets. Some of these systems, such as GABA, have been implicated in anxiety disorders for decades, but a recent greater understanding is enabling more sophisticated targeting of treatments. In other systems, including the neuropeptides, we have now developed the pharmacological tools in human subjects to begin exploring their relationship to anxiety disorders. We review GABA, serotonin, glutamate, noradrenaline, dopamine and some neuropeptides herein.
Export Options
About this article
Cite this article as:
Christmas D., Hood S. and Nutt D., Potential Novel Anxiolytic Drugs, Current Pharmaceutical Design 2008; 14 (33) . https://dx.doi.org/10.2174/138161208786848775
DOI https://dx.doi.org/10.2174/138161208786848775 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Elucidation of Abnormal Extracellular Regulated Kinase (ERK) Signaling and Associations with Syndromic and Non-syndromic Autism
Current Drug Targets Mechanisms And Prevention Of TAVI-Related Cerebrovascular Events
Current Pharmaceutical Design Effects of Statins on Blood Pressure: A Review of the Experimental and Clinical Evidence.
Current Vascular Pharmacology Highly Active Antiretroviral Therapy and Cardiovascular Complications in HIV-Infected Patients
Current Pharmaceutical Design A Review of the Ethnopharmacology, Phytochemistry and Pharmacology of Plants of the Maytenus Genus
Current Pharmaceutical Design 2-Isocyanatobenzonitrile and 2-Isothiocyanatobenzonitrile - Versatile Building Blocks in Organic Synthesis
Current Organic Chemistry Defining Pharmacokinetics for Individual Patient Dosimetry in Routine Radiopeptide and Radioimmunotherapy of Cancer: Australian Experience
Current Pharmaceutical Design Endothelins and the Role of Endothelin Antagonists in the Management of Posttraumatic Vasospasm
Current Pharmaceutical Design New Trends in Fiber-Optic Chemical and Biological Sensors
Current Analytical Chemistry Beta-Blockers in the Treatment of Dilated Cardiomyopathy: Which is the Best?
Current Pharmaceutical Design Pharmacological Therapy of Parkinson’s Disease: Current Options and New Avenues
Recent Patents on CNS Drug Discovery (Discontinued) Mast Cells as Targets of Pimecrolimus
Current Pharmaceutical Design Designed Multiple Ligands: Basic Research vs Clinical Outcomes
Current Medicinal Chemistry Neonatal Brain Hemorrhage (NBH) of Prematurity: Translational Mechanisms of the Vascular-Neural Network
Current Medicinal Chemistry Differentiating Walking from other Activities of Daily Living in Older Adults Using Wrist-based Accelerometers
Current Aging Science CB1 Cannabinoid Antagonists: Structure-Activity Relationships and Potential Therapeutic Applications
Current Topics in Medicinal Chemistry Agents Targeting Ras Signaling Pathway
Current Pharmaceutical Design Mechanisms in the Bed Nucleus of the Stria Terminalis Involved in Control of Autonomic and Neuroendocrine Functions: A Review
Current Neuropharmacology Torasemide in Hypertension and Heart Failure: Re-inventing Loop Diuretic Therapy?
Current Pharmaceutical Design Proteinase-Activated Receptor 2 (PAR2): A Challenging New Target for Treatment of Vascular Diseases
Current Pharmaceutical Design